A new blood pressure-lowering drug, aprocitentan, has shown promising results in the treatment of persistent hypertension in patients with chronic kidney disease. Scientists noted the potential promise of the drug.
Aprocitentan has shown efficacy and safety in the treatment of persistent hypertension in patients with stage III-IV chronic kidney disease. Results from the PRECISION study, presented at the American Society of Nephrology ASN 2023 Annual Meeting, are published on Medscape.
The main results after 4 weeks of treatment were a decrease in mean arterial pressure of 3.8 mmHg. while taking a daily dose of aprocitentan 12.5 mg and 3.7 mm Hg. with a daily dose of 25 mg compared with placebo. Average daily blood pressure decreased by 4.2 mm Hg. at a low dose of aprocitentan compared with placebo and by 5.9 mmHg. at high dose compared to placebo.
|The study included 730 patients, of whom 141 were diagnosed with stage III chronic kidney disease with an estimated glomerular filtration rate of 30 to 59 ml/min/1.73 m2.
Experts note that the number of patients with stage IV disease (with an estimated glomerular filtration rate of 15-29 ml/min/1.73 m2) was too few (21 patients). More research is needed to draw conclusions about the safety and effectiveness of the drug in this category.
If the drug receives US Food and Drug Administration (FDA) approval in 2024 (currently pending), it could represent a significant step in the treatment of patients with hypertension resistant to standard drugs, the authors said.